Published in J Nucl Med on January 15, 2010
Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem (2013) 1.34
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther (2014) 0.94
Analysis of vesicular monoamine transporter 2 polymorphisms in Parkinson's disease. Neurobiol Aging (2013) 0.94
Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest (2011) 0.93
Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease. PLoS One (2011) 0.88
Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol (2012) 0.87
Biomarkers of Parkinson's disease: current status and future perspectives. Drug Discov Today (2012) 0.86
Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization. BMC Med Genomics (2016) 0.83
Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab (2011) 0.83
Vesicular integrity in Parkinson's disease. Curr Neurol Neurosci Rep (2013) 0.82
PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev (2014) 0.82
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol (2014) 0.82
A phenotypic model recapitulating the neuropathology of Parkinson's disease. Brain Behav (2013) 0.79
Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One (2013) 0.79
PET imaging a MPTP-induced mouse model of Parkinson's disease using the fluoropropyl-dihydrotetrabenazine analog [18F]-DTBZ (AV-133). PLoS One (2012) 0.78
Mapping the target localization and biodistribution of non-radiolabeled VMAT2 ligands in rat brain. AAPS J (2014) 0.78
Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener (2017) 0.75
Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson's disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. PLoS One (2017) 0.75
hVMAT2: A Target of Individualized Medication for Parkinson's Disease. Neurotherapeutics (2016) 0.75
Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol (2014) 0.75
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
The Accelerated Child Survival and Development programme in west Africa: a retrospective evaluation. Lancet (2010) 6.56
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol Pharmacol (2004) 4.58
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat Cell Biol (2006) 3.12
WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ (2009) 3.10
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Street lighting disturbs commuting bats. Curr Biol (2009) 2.95
Levels and trends in under-5 mortality, 1990-2008. Lancet (2009) 2.86
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol (2011) 2.81
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron (2010) 2.75
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med (2009) 2.51
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet (2011) 2.50
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? Acta Neuropathol (2014) 2.25
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects. J Nucl Med (2012) 2.16
Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol (2002) 2.06
In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry (2004) 2.04
Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol Psychiatry (2003) 1.94
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med (2013) 1.93
Levels and trends in child mortality, 1990-2009. Lancet (2010) 1.92
Subtypes of progressive aphasia: application of the International Consensus Criteria and validation using β-amyloid imaging. Brain (2011) 1.92
Relation of addiction genes to hypothalamic gene changes subserving genesis and gratification of a classic instinct, sodium appetite. Proc Natl Acad Sci U S A (2011) 1.89
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement (2013) 1.87
IL-13-induced changes in the goblet cell density of human bronchial epithelial cell cultures: MAP kinase and phosphatidylinositol 3-kinase regulation. Am J Physiol Lung Cell Mol Physiol (2003) 1.86
Taxon-specific PCR for DNA barcoding arthropod prey in bat faeces. Mol Ecol Resour (2010) 1.84
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Fellatio by fruit bats prolongs copulation time. PLoS One (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nucl Med Biol (2005) 1.64
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
An aerial-hawking bat uses stealth echolocation to counter moth hearing. Curr Biol (2010) 1.60
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med (2013) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
SPECT imaging of herpes simplex virus type1 thymidine kinase gene expression by [(123)I]FIAU(1). Acad Radiol (2005) 1.55
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics (2014) 1.53
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine. J Nucl Med (2011) 1.50
Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol (2004) 1.49
Fluoro-pegylated (FPEG) imaging agents targeting Abeta aggregates. Bioconjug Chem (2007) 1.49
Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging (2012) 1.49
Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol (2006) 1.49
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res (2007) 1.44
The hearing gene Prestin reunites echolocating bats. Proc Natl Acad Sci U S A (2008) 1.44
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem (2007) 1.43
Testing times: do new prenatal tests signal the end of Down syndrome? N Z Med J (2013) 1.42
Molecular diet analysis of two african free-tailed bats (molossidae) using high throughput sequencing. PLoS One (2011) 1.41
Inflammation following stroke. J Clin Neurosci (2006) 1.40
Echolocation call intensity in the aerial hawking bat Eptesicus bottae (Vespertilionidae) studied using stereo videogrammetry. J Exp Biol (2005) 1.40